News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Forest Laboratories, Inc. (FRX) to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association Annual Meeting



5/4/2012 10:04:27 AM

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) Annual Meeting scheduled May 5-9, 2012 in Philadelphia, PA. Data on cariprazine, an investigational antipsychotic agent, includes additional details from a Phase III trial for acute mania in bipolar I disorder and results from an open-label extension study in schizophrenia. Separately, data on levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder (MDD), includes additional analyses of Phase III trial results.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES